NSE
Concord Biotech LimitedCONCORDBIO
Concord Biotech Limited is an NSE-listed company (CONCORDBIO).
AI-generated overview — verify before relying on it.
Net institutional flow
+₹331 Cr
Institutional buyers
2 in / 0 out
High-impact filings
1 · tilt Bullish
Next corporate action
Dividend - Rs 10.70 Per Share
ex 2025-09-03
Competitive landscape — the read
vs mapped peers| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | CONCORDBIOThis | +₹331 Cr | 5 | 1 | +1 | — | — |
| 2 | ACUTAAS | +₹98.2 Cr | 1 | — | — | +4 | 6 |
| 3 | AAVAS | +₹79.7 Cr | 5 | — | — | — | — |
| 4 | AADHARHFC | — | — | — | — | — | — |
| 5 | AARTIIND | +₹0 Cr | 4 | — | — | — | — |
| 6 | ACE | +₹0 Cr | 2 | — | — | — | — |
| 7 | ACMESOLAR | −₹80.9 Cr | 1 | — | — | +3 | 6 |
| 8 | ABLBL | −₹314.4 Cr | 29 | — | — | — | — |
| 9 | ABFRL | −₹730.3 Cr | 13 | — | +1 | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
Timeline — CONCORDBIO day by day
- 2026-06-13FilingConcord Biotech Limited has informed the Exchange about Schedule of meetInvestor Call
- 2026-06-12FilingConcord Biotech Limited has informed the Exchange regarding 'Completion of ANVISA Inspection conducted by the Updates
- 2026-06-10FilingConcord Biotech Secures Abbreviated New Drug Application (ANDA) Approval for Tofacitinib Tablets, 5 mg and 10 Order Win
- 2026-02-25BulkBUY · ₹75.1 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-02-25BulkSELL · ₹75.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2025-09-03ActionDividend - Rs 10.70 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Scope the deal/action portion with the period chips below.
Filings that matter
- 2
- 2UpdatesNeutral
Completion of ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility'.
Source PDF → - 8
2 deals · 2026-02-25 → 2026-02-25
| Date | Counterparty | Investor type | Side | Value |
|---|---|---|---|---|
| 2026-02-25 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹75.1 Cr |
| 2026-02-25 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹75.2 Cr |
2 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
Results & transcripts
Financial results
None yet.
News & chatter on CONCORDBIO
RSS News
0No recent news.
Google News RSS — links open the source.
The Dispatch
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.